Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
KIR3DL1 Antibody (MM0443-1L34) - Azide and BSA Free, Novus Biologicals™

Mouse Monoclonal Antibody
Supplier: Novus Biologicals NBP211763
Description
KIR3DL1 Monoclonal specifically detects KIR3DL1 in Human samples. It is validated for Flow Cytometry, CyTOF-ready, Block/Neutralize.Specifications
| KIR3DL1 | |
| Monoclonal | |
| LYOPH | |
| Flow Cytometry 1:50-1:100, CyTOF-ready, Block/Neutralize | |
| ADM64608.1 | |
| KIR3DL1 | |
| Human recombinant KIR3DL1 | |
| 0.1 mg | |
| Immunology | |
| 3811 | |
| Reconstitute with sterilized PBS to a final concentration of 0.5 mg/ml. | |
| Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles. | |
| IgG1 |
| Flow Cytometry, Blocking Assay, CyTOF | |
| MM0443-1L34 | |
| Unconjugated | |
| Lyophilized from a 0.2 μm filtered solution in PBS. 0.025 mg size is provided in liquid form, PBS with No Preservative | |
| AMB11, CD158 antigen-like family member E, CD158E, CD158e antigen, CD158e1, CD158e1/2, CD158e2, cl-11, cl-2, HLA-BW4-specific inhibitory NK cell receptor, killer cell immunoglobulin-like receptor 3DL1, killer cell immunoglobulin-like receptor, three domains, long cytoplasmic tail1,nkat3, killer Ig receptor, KIR antigen 3DL1, KIR3DL1/S1, KIR3DS1, MGC119726, MGC119728, MGC126589, MGC126591, MHC class I NK cell receptor, Natural killer-associated transcript 3, NKAT-3, NKAT3KIR, NKB1B, NKB1CD158E1, NK-receptor, p70 killer cell inhibitory receptor, p70 natural killer cell receptor clones CL-2/CL-11, p70 NK receptor CL-2/CL-11 | |
| Mouse | |
| Protein G purified | |
| RUO | |
| Primary | |
| This antibody was selected for its ability to specifically detect human KIR3DL1. | |
| Human | |
| Purified |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
For Research Use Only
Spot an opportunity for improvement?Share a Content Correction